Engitix Therapeutics have announced that they will be the latest life science company to move their headquarters to White City Place, with plans to move their laboratory space later this year.
Engitix is an exciting biotech company developing a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM)-based discovery platform. The use of physiologically realistic human in vitro models is transforming the ability to identify new drug targets, determine biological mechanisms of action and increase the success rate of therapeutic candidates gaining regulatory approval.
The announcement of Engitix's relocation is the latest in a host of life science companies which have moved to White City Place, joining Gama Delta, Autolus and Synthace, as well as global pharmaceutical company Novartis who also relocated their UK headquarters to the campus.
Stephen Brindle, COO, Engitix said:
“The move to WestWorks is a hugely important milestone for our business as we take the next steps in developing our innovative drug development platform. Being located at White City Place gives us access to world class facilities, access to an established life sciences network, and will help us attract the best talent to Engitix also.”